Literature DB >> 14735143

The HLA-DR2 haplotype is associated with an increased proliferative response to the immunodominant CD4(+) T-cell epitope in human interferon-beta.

M Stickler1, A M Valdes, W Gebel, O J Razo, N Faravashi, R Chin, N Rochanayon, F A Harding.   

Abstract

Human CD4(+) T-cell epitopes were identified in interferon-beta (IFN-beta)-1b. A prominent peptide epitope region was found that induced a proliferative response in 16% of all donors tested. Responses corresponded to the presence of the HLA-DR2 haplotype. Responsive donors expressing the HLA-DQ6 allele showed an increased level of proliferation to the epitope as compared to peptide-responsive HLA-DQ6 negative donors. A similar result was found for HLA-DR15-expressing donors. PBMC from donors expressing HLA-DR15 were more likely to proliferate in response to IFN-beta in a whole-protein in vitro assay than donors who did not carry this haplotype. It is striking that the common DQ6 allele HLA-DQB1(*)0602 is found in linkage disequilibrium with HLA-DRB1(*)1501, and this combination defines the HLA genotype associated with the development of multiple sclerosis. The HLA association between a response to IFN-beta and MS might explain the prevalence of neutralizing antibody development, and may underlie the etiology of the disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14735143     DOI: 10.1038/sj.gene.6364027

Source DB:  PubMed          Journal:  Genes Immun        ISSN: 1466-4879            Impact factor:   2.676


  5 in total

1.  Immunogenicity of protein therapeutics: The key causes, consequences and challenges.

Authors:  Matthew P Baker; Helen M Reynolds; Brooke Lumicisi; Christine J Bryson
Journal:  Self Nonself       Date:  2010-10

2.  The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions.

Authors:  Fiona A Harding; Marcia M Stickler; Jennifer Razo; Robert B DuBridge
Journal:  MAbs       Date:  2010-05-01       Impact factor: 5.857

3.  Human leukocyte antigen genes and interferon beta preparations influence risk of developing neutralizing anti-drug antibodies in multiple sclerosis.

Authors:  Jenny Link; Malin Lundkvist Ryner; Katharina Fink; Christina Hermanrud; Izaura Lima; Boel Brynedal; Ingrid Kockum; Jan Hillert; Anna Fogdell-Hahn
Journal:  PLoS One       Date:  2014-03-07       Impact factor: 3.240

4.  Quantitative analysis of the CD4+ T cell response to therapeutic antibodies in healthy donors using a novel T cell:PBMC assay.

Authors:  Heidi S Schultz; Stine Louise Reedtz-Runge; B Thomas Bäckström; Kasper Lamberth; Christian R Pedersen; Anne M Kvarnhammar
Journal:  PLoS One       Date:  2017-05-31       Impact factor: 3.240

5.  Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS.

Authors:  Till F M Andlauer; Jenny Link; Dorothea Martin; Malin Ryner; Christina Hermanrud; Verena Grummel; Michael Auer; Harald Hegen; Lilian Aly; Christiane Gasperi; Benjamin Knier; Bertram Müller-Myhsok; Poul Erik Hyldgaard Jensen; Finn Sellebjerg; Ingrid Kockum; Tomas Olsson; Marc Pallardy; Sebastian Spindeldreher; Florian Deisenhammer; Anna Fogdell-Hahn; Bernhard Hemmer
Journal:  BMC Med       Date:  2020-11-04       Impact factor: 8.775

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.